sthakur January 13, 2021
Neuromyelitis Optica Spectrum Disorder

 

DelveInsight has launched a new report on   Neuromyelitis Optica Spectrum Disorder Market

 

Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years. In its early stages, NMOSD may be confused with multiple sclerosis (MS).

 

Get a free sample copy- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

 

Neuromyelitis Optica Spectrum Disorder Market size by therapies, covering the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan from 2017 to 2030

 

Neuromyelitis Optica Spectrum Disorder Treatment

Greater than 95% of patients with NMOSD report no relatives with the disease, but approximately 3% report having other relatives with the condition. There is a strong association with a personal or family history of autoimmunity, which are present in 50% of cases. NMOSD is regarded as an autoimmune disease though the exact cause for the autoimmunity is unknown.

For acute attacks, the standard treatment is high-dose intravenous corticosteroids, typically methylprednisolone. Plasma exchange may be effective in patients who experience acute severe attacks that do not response to intravenous corticosteroids. For long-term suppression of the disease, a variety of immunosuppressive drugs are regarded by many clinicians as first-line therapy Symptom treatment may also involve the use of low doses of carbamazepine to control paroxysmal (sudden) tonic spasms that often occur during attacks of NMOSD and antispasticity agents to treat long term complication of spasticity that frequently develops in those with permanent motor deficits.

 

Key companies of the NMOSD report

  • Alexion Pharmaceuticals
  • Viela Bio

 

Neuromyelitis Optica Spectrum Disorder Market Insight

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a heterogeneous but well-defined clinical entity, distinct from other neurologic and systemic inflammatory diseases, and treatment is poised for expansion. Treatment of NMO includes both the management of acute attacks and the prevention of future exacerbations. The goal of acute therapy is to minimize irreversible damage and accelerate recovery. Preventative therapy should lower the frequency and severity of future exacerbations.

 

Neuromyelitis Optica Spectrum Disorder Treatment Market

To summarize, a better and clear understanding of the pathogenesis of Neuromyelitis Optica Spectrum Disorder (NMOSD) will significantly improve the treatment regimens and development of novel therapies. With this, several companies have started working toward the development of new therapeutic options. The market is expected to experience a positive growth in the coming years owing to the already prescribed products along with the launch of distinctive emerging therapies in the coming years.

Furthermore, pharmaceutical companies, such as Chugai, Bio-Thera Solutions, Remegen, Harbour BioMed and others are actively working toward the development of potential therapies in order to fulfill the unmet medical needs of the currently used therapeutics.

Overall, the rise in Neuromyelitis Optica Spectrum Disorder population, increased funding by governmental bodies, and vigorous R&D activities are further expected to propel the Neuromyelitis Optica Spectrum Disorder market during the forecast period (2020–2030).

 

Neuromyelitis Optica Spectrum Disorder Market Report Scope

  • The report covers the descriptive overview of Neuromyelitis Optica Spectrum Disorder (NMOSD), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Neuromyelitis Optica Spectrum Disorder (NMOSD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Neuromyelitis Optica Spectrum Disorder (NMOSD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Neuromyelitis Optica Spectrum Disorder (NMOSD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Neuromyelitis Optica Spectrum Disorder (NMOSD) market

 

Get a free sample copy- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

 

Table of content

  1. Key Insights
  2. Executive Summary of Neuromyelitis Optica Spectrum Disorder (NMOSD)
  3. Competitive Intelligence Analysis for Neuromyelitis Optica Spectrum Disorder (NMOSD)
  4. Neuromyelitis Optica Spectrum Disorder (NMOSD): Market Overview at a Glance
  5. Neuromyelitis Optica Spectrum Disorder (NMOSD): Disease Background and Overview
  6. Patient Journey
  7. Neuromyelitis Optica Spectrum Disorder (NMOSD) Epidemiology and Patient Population
  8. Treatment Algorithm, Current Treatment, and Medical Practices
  9. Unmet Needs
  10. Key Endpoints of Neuromyelitis Optica Spectrum Disorder Treatment
  11. Marketed Products
  12. Emerging Therapies
  13. Neuromyelitis Optica Spectrum Disorder (NMOSD): Seven Major Market Analysis
  14. Attribute analysis
  15. 7MM: Market Outlook
  16. Access and Reimbursement Overview of Neuromyelitis Optica Spectrum Disorder (NMOSD)
  17. KOL Views
  18. Market Drivers
  19. Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer
  23. About DelveInsight

 

Get a free sample copy- https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

 

Why should you buy this NMOSD report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Neuromyelitis Optica Spectrum Disorder  NMOSD market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder (NMOSD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Neuromyelitis Optica Spectrum Disorder (NMOSD) market
  • To understand the future market competition in the Neuromyelitis Optica Spectrum Disorder market

 

View related reports

 

You can check our latest blogs- DelveInsight Blog    

 

Contact us

Shruti Thakur

[email protected]

+91-9650213330

https://www.delveinsight.com/

LinkedIn | Facebook | Twitter

https://mmcthemonitor.com/